Category

M&A

Acquisition PB Bake-off by Dutch Bakery LawyersM&ANiels HofkesPrivate EquityTrack Record

Acquisition PB Bake-off by Dutch Bakery

We advised Dutch Bakery, a portfolio company of Standard Investment, on the acquisition of PB Bake-off. The company, incorporated in 1991, is one of the leading producers of Viennoiserie (luxury sweet pastry), croissants and cheese stems in the Netherlands and will be integrated into Dutch Bakery. The acquisition fits perfectly with Dutch Bakery's strategy, among other things because Dutch Bakery will have access to significant additional production capacity. For example, PB Bake-off has a state-of-the-art croissant line with a capacity of 140 million croissants per year and the company has a very large freezer facility. This will further facilitate the rapid growth of Dutch Bakery. The transaction also offers good opportunities for widening the Dutch Bakery assortment and increasing the sales market for PB Bake-off.
Niels_Admin
31 March 2017
Nexguard logo
Kudelski Group acquires NexGuard Labs from Civolution HomepageLawyersM&AMarcel van de VorstTrack Record

Kudelski Group acquires NexGuard Labs from Civolution

We advised Civolution, the leading provider of technology and solutions for identifying, managing and monetizing content, on the sale of NexGuard Labs to Kudelski, who acquired 100% of all outstanding shares in the capital of NexGuard Labs BV. NexGuard Labs is a leader in digital content watermarking solutions. This transaction is the third and final successful exit of a Civolution business unit. Previously, we advised Civolution on the sale of its Teletrax business to 4C Insights Inc., a data science software company that is powering the future of advertising. Teletrax provides the world's most advanced and accurate solution for real-time television analytics and cross-screen synchronized marketing campaigns. 4C is backed by Jump Capital based in Chicago (USA). * We also advised Civolution on the sale of its audio watermarking unit to Kantar Media (WPP), a world leader in audience measurement. Civolution’s audio watermarking technology is recognized as world leading and is deployed in hundreds of TV channels worldwide for the purpose of audience measurement and second screen synchronization. * *  Marcel van de Vorst led the latter two transactions whilst at previous law firm.
Niels_Admin
7 July 2016
Sale of GreenPeak to Qorvo LawyersM&AMarcel van de VorstNiels HofkesTrack Record

Sale of GreenPeak to Qorvo

We advised Gimv, Robert Bosch Venture Capital and DFJ Esprit on the sale of all outstanding shares in GreenPeak Technologies B.V. to Qorvo. GreenPeak is a fabless semiconductor/system company and makes ZigBee semiconductor products and software technologies for Smart Home data communications and the Internet of Things. Previously we advised GreenPeak Technologies on its 2013 equity financing round by existing shareholders comprising Gimv, Robert Bosch Venture Capital GmbH and DFJ Esprit II LP. We also advised on the company’s prior equity financing rounds and the acquisition of Ubiwave since 2007. * *  Marcel van de Vorst led these earlier transactions whilst at previous law firm.
Niels_Admin
2 May 2016
Varitex sold to Lohmann & Rauscher LawyersM&AMarcel van de VorstTrack Record

Varitex sold to Lohmann & Rauscher

We advised the sellers of Varitex N.V. to Lohmann & Rauscher (L&R), a leading international supplier of high quality, forward-looking medical devices and hygiene products – ranging from conventional dressing material to modern treatment and nursing systems. Varitex has been developing, producing and marketing compression stockings and other products under the brand of the same name – Varitex - on the Dutch market since its founding in 1947. In addition, Varitex also manufactures a range of private label products, for which it is already a long-term supplier of the British L&R subsidiary Activa Healthcare Ltd.
Niels_Admin
2 May 2016
Acquisition of Acerta Pharma by Astra Zeneca M&ANiels HofkesTrack Record

Acquisition of Acerta Pharma by Astra Zeneca

We advised BOM Capital on the sale of its shares in Acerta Pharma to Astra Zeneca. BOM Capital was one of the early investors in Acerta Pharma. Astra Zeneca has taken a 55% stake in Acerta Pharma and an option to acquire the remaining 45% interest. This sale is after BioNovion the second successful exit in biotech for BOM Capital in 2015, is the largest in the history of BOM Capital and the largest biotech deal so far in the Netherlands.
Niels_Admin
17 December 2015
BOM Capital sells shares in BioNovion to Aduro Biotech Eveline MutsaersM&ANiels HofkesTrack Record

BOM Capital sells shares in BioNovion to Aduro Biotech

We advised BOM Capital on the sale of its shares in BioNovion to Aduro Biotech. The company, based on the Pivot Park in Oss, is the new European headquarters of Nasdaq-listed Aduro Biotech and renamed in Aduro Biotech Europe. Aduro acquired BioNovion to broaden its technological portfolio and to increase the potential of immunotherapy. BioNovion develops monoclonal antibody therapies against cancer, on the basis of their unique platform technology and expertise in the field of immune therapy of cancer.
Niels_Admin
15 November 2015